Cargando…
Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
Rationale: Many cancers have evolved different mechanisms to evade immune surveillance. Macrophages, the innate defense of the immune system, are limited in their phagocytosis by CD47 anti-phagocytic signaling expressed on the surface of tumor cells. Although the CD47 monoclonal antibody (aCD47) str...
Autores principales: | Li, Chang, Liu, Yubo, Li, Dan, Wang, Qiu, Zhou, Shuang, Zhang, Haotian, Wang, Yongjun, He, Zhonggui, Liu, Hongzhuo, Sun, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254232/ https://www.ncbi.nlm.nih.gov/pubmed/35832081 http://dx.doi.org/10.7150/thno.72310 |
Ejemplares similares
-
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021) -
Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023) -
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian
Cancer
por: Luo, Xukai, et al.
Publicado: (2023) -
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)